Mohlo by se vám také líbit

Více informací o knize Risk-sharing in the Pharmaceutical Industry

• Parametry knihy
• Anotace
• Oblíbené z jiného soudku

Nákupem získáte 331 bodů

Anotace knihy

The costs of developing a new drug have reached record levels in the pharmaceutical industry. As any failure of a new drug candidate can lead to significant losses, many pharmaceutical companies are looking for new approaches to reduce their exposure to R&D risks. In this context, the book deals with the topic of out-licensing as a novel form of risk-sharing collaborations. The phenomenon of out-licensing is illustrated by three major case studies of Novartis, Schering and Roche as well as several smaller case studies. In addition, the Noble Prize awarded economic theory of Adverse Selection is applied to analyze the topic theoretically. The gained insights allow identifying the critical parameters of out-licensing collaborations and thereby provide R&D managers with recommendations on how to conclude and manage this type of deals more effectively.

Parametry knihy

Zařazení knihy Knihy v angličtině Economics, finance, business & management Industry & industrial studies Manufacturing industries

• Plný název: Risk-sharing in the Pharmaceutical Industry
• Podnázev: The Case of Out-licensing
• Autor: Gerrit Reepmeyer
• Jazyk: Angličtina
• Vazba: Brožovaná
• Počet stran: 297
• EAN: 9783790816679
• ISBN: 3790816671
• ID: 01737960
• Nakladatelství: Springer-Verlag Berlin and Heidelberg GmbH & Co. KG
• Hmotnost: 970 g
• Rozměry: 235 × 155 × 17 mm
• Datum vydání: 05. December 2005

Oblíbené z jiného soudku

---

---

---